





**FIGURE 1: In Vitro Dissolution Profiles of 100 mg Tramadol HCl ER Tablets Formulated According to  
Lot Nos. 2159, 2162 and 2165**





**FIGURE 2: Mean Plasma Tramadol Concentrations (n=14)**

**FIGURE 3: Mean O-Desmethyltramadol (M1) Concentrations (N=14)**

**FIGURE 4: Mean Day 1 Tramadol Concentrations (N=15)**

**FIGURE 5: Mean Day 5 Steady State Tramadol Concentration (N=15)**



**FIGURE 6: Mean Day 1 M1 Concentration (N=15)**

**FIGURE 7: Mean Day 5 Steady State M1 Concentration (N=15)**




FIGURE 8: Mean Single Dose Tramadol Concentration (N=15)





FIGURE 9: Mean Steady State Tramadol Concentration (N=15)






**FIGURE 10: Mean Single Dose M1 Concentration (N=15)**


FIGURE 11: Mean Steady State M1 Concentration (N=15)




**FIGURE 12: In Vitro Dissolution Profiles of 100 mg Tramadol HCl ER Tablets Formulated According to Lot Nos. 1 to 4**



**FIGURE 13: In Vitro Dissolution Profile of a 200 mg Tramadol HCl ER Tablet**



**FIGURE 14: In Vitro Dissolution Profiles of 200 mg Tramadol HCl ER Tablets Formulated According to Lot Nos. 5 to 7**






Figure 15




Figure 16




Figure 17




Figure 18




Figure 19




Figure 20




Figure 21




Figure 22

**LS Mean Change from Baseline to Average  
of Weeks 1-12 in Arthritis Pain Intensity VAS Score  
(Primary Variable)**




Figure 23

**LS Mean Change from Baseline to Different Study Time Points in  
Arthritis Pain Intensity VAS Scores  
(Primary Variable)**




Figure 24

### Comparison of the Tramadol HCl ER and Placebo (Secondary Variables)




Figure 25

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**